Are you Dr. Bedrosian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 51 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
26 Landsdowne Street
Cambridge, MA 02139Phone+1 617-494-0400Fax+1 617-494-8144
Summary
- Dr. Camille Bedrosian, MD is an oncologist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Massachusetts and North Carolina.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1988- Duke University HospitalResidency, Internal Medicine, 1984 - 1986
Newton-Wellesley HospitalInternship, Internal Medicine, 1983 - 1984
Harvard Medical SchoolClass of 1983
Certifications & Licensure
MA State Medical License 1998 - 2024
NC State Medical License 1987 - 2024- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 200 citationsEculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.Larry A. Greenbaum, Marc Fila, Gianluigi Ardissino, Samhar I. Al-Akash, Jonathan R. Evans
Kidney International. 2016-03-01 - 218 citationsTerminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label TrialFadi Fakhouri, Maryvonne Hourmant, Josep M. Campistol, Spero R. Cataland, Mario Espinosa
American Journal of Kidney Diseases. 2016-07-01 - 289 citationsEfficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studiesChristoph Licht, Larry A. Greenbaum, Petra Muus, Sunil Babu, Camille L. Bedrosian
Kidney International. 2015-05-01
Press Mentions
Amylyx Touts ‘Encouraging’ Phase 2 Alzheimer’s Trial DataAugust 15th, 2024- Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationAugust 12th, 2024
- Three Misconceptions About the Accelerated Drug Approval PathwayMay 10th, 2023
- Join now to see all
